Newsquawk Logo

Vertex Pharmaceuticals (VRTX) Q1 2026 (USD): Adj. EPS 4.47 (exp. 4.24), Revenue 2.99bln (exp. 2.99bln)

Vertex Pharmaceuticals reported Q1 2026 adjusted EPS of 4.47, beating expectations of 4.24, indicating stronger-than-expected profitability.

Newsquawk StaffPublished On the live feed at — 9 more headlines followed before this page went public
Newsquawk headlinesUTC

Palantir Technologies (PLTR) Q1 2026 (USD): Adj. EPS 0.33 (exp. 0.28), Revenue 1.63bln (exp. 1.54bln), Adj. net income 856.5mln (exp. 718.1mln)

Paramount Skydance (PSKY) Q1 2026 (USD): Adj. EPS 0.23 (exp. 0.15), Revenue 7.35bln (exp. 7.27bln), Paramount+ subscribers 79.6mln

Vertex Pharmaceuticals (VRTX) Q1 2026 (USD): Adj. EPS 4.47 (exp. 4.24), Revenue 2.99bln (exp. 2.99bln)

US CENTCOM says earlier today, Sea Hawk and US Army AH-64 Apache helicopters were used to eliminate Iranian small boats threatening commercial shipping

US CBP says IEEPA refund transactions are going to begin as early as May 12th

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.

Guidance:

  • FY revenue 12.95-13.1bln (exp. 13.05bln).
Context

While revenue met estimates at 2.99 billion, the guidance for FY revenue is slightly lower than consensus, suggesting potential caution in growth outlook. This mixed result could influence market sentiment, particularly in the biotech sector, as investors assess the implications for future performance.

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.